Business sale royalty expense
Bristol-Myers Squibb·Products & Services·1 segment
Breakdown
Segments
Amylin, Onglyza, and FarxigaView metric
| Segment | FY'24 | FY'25 |
|---|---|---|
| Amylin, Onglyza, and Farxiga | $96M | $88M |
| Total | $96M | $88M |
All segment values are derived from annual filings.